Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marc Peter Bonaca, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Marc Bonaca and Eugene Braunwald.
Marc Bonaca
Connection Strength
6.544
Eugene Braunwald
  1. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):934-943.
    View in: PubMed
    Score: 0.786
  2. Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48. Eur Heart J Cardiovasc Pharmacother. 2021 Dec 28.
    View in: PubMed
    Score: 0.244
  3. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2021 09 07; 10(17):e020446.
    View in: PubMed
    Score: 0.239
  4. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. J Am Heart Assoc. 2021 02 16; 10(4):e017008.
    View in: PubMed
    Score: 0.230
  5. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. Eur Heart J. 2020 05 01; 41(17):1625-1632.
    View in: PubMed
    Score: 0.218
  6. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. J Am Heart Assoc. 2018 11 20; 7(22):e009260.
    View in: PubMed
    Score: 0.197
  7. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation. 2018 02 13; 137(7):684-692.
    View in: PubMed
    Score: 0.183
  8. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol. 2017 Sep 12; 70(11):1368-1375.
    View in: PubMed
    Score: 0.182
  9. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial. JACC Cardiovasc Interv. 2016 10 24; 9(20):2157-2164.
    View in: PubMed
    Score: 0.171
  10. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation. 2016 Sep 20; 134(12):861-71.
    View in: PubMed
    Score: 0.169
  11. Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. J Am Coll Cardiol. 2016 07 19; 68(3):322-323.
    View in: PubMed
    Score: 0.168
  12. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol. 2016 Jul 01; 1(4):425-32.
    View in: PubMed
    Score: 0.167
  13. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016 Jun 14; 67(23):2719-2728.
    View in: PubMed
    Score: 0.164
  14. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation. 2016 Mar 08; 133(10):997-1005.
    View in: PubMed
    Score: 0.162
  15. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016 Apr 07; 37(14):1133-42.
    View in: PubMed
    Score: 0.159
  16. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016 Jan 21; 37(4):400-8.
    View in: PubMed
    Score: 0.159
  17. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015 09 24; 373(13):1274-5.
    View in: PubMed
    Score: 0.158
  18. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015 May 07; 372(19):1791-800.
    View in: PubMed
    Score: 0.153
  19. Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. Eur Heart J Acute Cardiovasc Care. 2015 Oct; 4(5):431-40.
    View in: PubMed
    Score: 0.150
  20. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2309-17.
    View in: PubMed
    Score: 0.150
  21. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2318-26.
    View in: PubMed
    Score: 0.150
  22. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014 Apr; 167(4):437-444.e5.
    View in: PubMed
    Score: 0.141
  23. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013 Apr 09; 127(14):1522-9, 1529e1-6.
    View in: PubMed
    Score: 0.133
  24. Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2012 Jul 24; 60(4):332-8.
    View in: PubMed
    Score: 0.127
  25. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation. 2012 Jan 31; 125(4):577-83.
    View in: PubMed
    Score: 0.122
  26. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):203-10.
    View in: PubMed
    Score: 0.113
  27. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol. 2010 May 11; 55(19):2118-24.
    View in: PubMed
    Score: 0.109
  28. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009 Jun 02; 119(21):2758-64.
    View in: PubMed
    Score: 0.102
  29. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 02 16; 143(7):685-695.
    View in: PubMed
    Score: 0.058
  30. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circ Genom Precis Med. 2021 02; 14(1):e003006.
    View in: PubMed
    Score: 0.057
  31. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 02 02; 143(5):470-478.
    View in: PubMed
    Score: 0.057
  32. Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiol. 2020 11 01; 5(11):1255-1262.
    View in: PubMed
    Score: 0.056
  33. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2020 03 17; 75(10):1095-1106.
    View in: PubMed
    Score: 0.054
  34. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019 10 01; 5(4):200-206.
    View in: PubMed
    Score: 0.052
  35. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). Am J Cardiol. 2019 01 01; 123(1):145-152.
    View in: PubMed
    Score: 0.049
  36. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. J Am Coll Cardiol. 2018 02 06; 71(5):489-496.
    View in: PubMed
    Score: 0.047
  37. Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups. J Am Coll Cardiol. 2018 01 02; 71(1):108.
    View in: PubMed
    Score: 0.046
  38. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol. 2017 Aug 01; 70(5):527-538.
    View in: PubMed
    Score: 0.045
  39. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017 Mar 28; 69(12):1549-1559.
    View in: PubMed
    Score: 0.044
  40. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clin Chem. 2017 Jan; 63(1):307-315.
    View in: PubMed
    Score: 0.043
  41. Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial. Eur Heart J Acute Cardiovasc Care. 2017 Mar; 6(2):164-172.
    View in: PubMed
    Score: 0.042
  42. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. Circulation. 2016 Jul 26; 134(4):304-13.
    View in: PubMed
    Score: 0.042
  43. Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50. J Am Heart Assoc. 2016 07 18; 5(7).
    View in: PubMed
    Score: 0.042
  44. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016 Jun 14; 67(23):2732-2740.
    View in: PubMed
    Score: 0.041
  45. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol. 2016 Mar 15; 67(10):1145-1154.
    View in: PubMed
    Score: 0.041
  46. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50). Am J Cardiol. 2016 Apr 01; 117(7):1055-8.
    View in: PubMed
    Score: 0.040
  47. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50. Circulation. 2015 Nov 17; 132(20):1871-9.
    View in: PubMed
    Score: 0.039
  48. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016 Jan 21; 37(4):390-9.
    View in: PubMed
    Score: 0.039
  49. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015 Mar 19; 4(3):e001505.
    View in: PubMed
    Score: 0.038
  50. Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T. Clin Cardiol. 2015 Apr; 38(4):230-5.
    View in: PubMed
    Score: 0.038
  51. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation. 2015 Mar 24; 131(12):1047-53.
    View in: PubMed
    Score: 0.038
  52. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014 Sep 10; 312(10):1006-15.
    View in: PubMed
    Score: 0.037
  53. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). J Am Coll Cardiol. 2014 Apr 29; 63(16):1644-53.
    View in: PubMed
    Score: 0.035
  54. Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. Clin Chem. 2014 Jan; 60(1):158-64.
    View in: PubMed
    Score: 0.034
  55. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013 Mar; 44(3):691-8.
    View in: PubMed
    Score: 0.033
  56. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012 Oct 13; 380(9850):1317-24.
    View in: PubMed
    Score: 0.032
  57. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 Apr 12; 366(15):1404-13.
    View in: PubMed
    Score: 0.031
  58. Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart. 2012 May; 98(10):786-91.
    View in: PubMed
    Score: 0.031
  59. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012 Jan; 58(1):257-66.
    View in: PubMed
    Score: 0.030
  60. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009 Sep; 158(3):335-341.e3.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.